What are the main side effects of Kisspeptin-54?

Kisspeptin-54 side effects and warning signals include Facial flushing, Nausea, Headache, Injection site discomfort, and Hot flashes (related to gonadotropin surge).

What evidence level is Kisspeptin-54?

Kisspeptin-54 is rated Level C; the listed research status is Phase 2.

Sexual Health / Level C / Phase 2 / Last reviewed 2026-04-04

Kisspeptin-54 Evidence Guide

Kisspeptin-54 has Phase 2 human data on HPG axis activation, showing LH pulse stimulation and potential applications in infertility and hypothalamic amenorrhea. The mechanism - upstream of GnRH - is genuinely differentiated. Evidence is early but comes from well-conducted university-based human trials. A credible emerging candidate for HPG axis fertility research, though far behind GnRH analogs in development stage.

Our Take

Best for: HPG axis activation research, hypothalamic amenorrhea, male and female fertility investigation
Evidence grade: Level C
Confidence: Moderate
Starting point: 6.4nmol/kg IV bolus (research doses from human studies)

Benefits and Evidence

LH/FSH Stimulation: Level B, includes human evidence - Intravenous and subcutaneous kisspeptin-54 administration robustly stimulates LH secretion in healthy volunteers and in patients with reproductive disorders. The LH response is mediated entirely through GnRH release.
Oocyte Maturation Trigger (IVF): Level C, includes human evidence - Phase 2 trials using kisspeptin-54 as an oocyte maturation trigger in IVF showed comparable oocyte yield with potentially lower risk of ovarian hyperstimulation syndrome compared to hCG.
Reproductive Axis Activation: Level C, includes human evidence - Studies in patients with hypothalamic amenorrhea demonstrate that kisspeptin can restore pulsatile LH secretion, suggesting therapeutic potential for functional hypogonadism.

Side Effects and Warnings

Facial flushing
Nausea
Headache
Injection site discomfort
Hot flashes (related to gonadotropin surge)
Investigational - not approved for clinical use
Tachyphylaxis observed with continuous or repeated dosing
May cause ovarian hyperstimulation in susceptible patients

Research Dosage References

<strong>Intravenous</strong> - 0.3-1.0 nmol/kg - Single bolus (research) - Research doses for studying acute gonadotropin responses. Produces rapid LH rise within 30-60 minutes.
<strong>Subcutaneous</strong> - 6.4-12.8 nmol/kg - Single or repeated doses - Subcutaneous route used in IVF trigger studies. Higher doses required than IV due to bioavailability.

Mechanism of Action

Kisspeptin-54 activates the KISS1R receptor on GnRH neurons: 1. KISS1R/GPR54 activation: Binds to the kisspeptin receptor on hypothalamic GnRH neurons, stimulating GnRH release through Gq/11 signaling, phospholipase C activation, and calcium mobilization. 2. Upstream GnRH regulation: Acts as the primary gatekeeper of the reproductive axis, integrating metabolic, circadian, and stress signals to modulate GnRH secretion. 3. LH pulse generation: Kisspeptin neurons in the arcuate nucleus function as the GnRH pulse generator, with kisspeptin/neurokinin B/dynorphin (KNDy) neurons coordinating pulsatile GnRH release. 4. Puberty initiation: Increased kisspeptin signaling at puberty activates the reproductive axis. Exogenous kisspeptin administration potently stimulates gonadotropin release.

Legal Status

Investigational. Not FDA-approved. Available for research purposes and in clinical trials. Not a controlled substance.

Primary Sources

Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization. Journal of Clinical Investigation, 2015.
Kisspeptin administration stimulates gonadotropin release in patients with hypogonadotropic hypogonadism. Journal of Clinical Endocrinology & Metabolism, 2014.
The role of kisspeptin in reproductive physiology and human disease. Human Reproduction Update, 2014.